Ospedale dell'Angelo di Mestre
- Address
- lock Available on a paid plan
Ospedale dell'Angelo di Mestre - Respiratory Disease Research
Ospedale dell'Angelo di Mestre is engaged in advanced clinical research focused on chronic respiratory diseases, with particular expertise in evaluating novel therapeutic interventions for patients with severe pulmonary conditions. The center participates in multinational studies investigating innovative combination therapies designed to improve patient outcomes and quality of life.
- Chronic Obstructive Pulmonary Disease (COPD) management and treatment optimization
- Cardiopulmonary outcome assessment in respiratory disease
- Evaluation of triple therapy combinations and bronchodilator interventions
The center's research portfolio emphasizes the investigation of metered-dose inhaler therapies combining multiple active compounds, including budesonide, glycopyrronium, and formoterol fumarate. Their work contributes to understanding how advanced combination triple therapy compares with dual bronchodilator approaches in preventing severe cardiopulmonary events and improving clinical outcomes for COPD patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 65 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 61 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ospedale dell'Angelo di Mestre
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy of MC0518 Allogeneic Mesenchymal Stromal Cells in Adult Patients with Grade II–IV Acute Graft-Versus-Host Disease Refractory to Corticosteroids and Ruxolitinib | Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia | Phase II | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 65 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 7 | Unknown | 2020-04-24 | 2024-10-17 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.